2023-04-24 10:27:39 ET
- Qualigen Therapeutics ( NASDAQ: QLGN ) said it had received a letter from the Nasdaq as it had failed to file its annual report on Form 10-K for the year.
- In March, the Company filed notification of Late Filing on Form 12b-25, indicating that the filing of its Form 10-K will be delayed until after the completion of the accounting and disclosures related to the Company’s acquisition of a majority interest in NanoSynex included in its Annual Report.
- The Company was unable to complete and file the Form 10-K prior to April 17, the extension period provided by the Form 12b-25, due to its acquisition and additional information and investigation needed in relation to its financial statements to complete the audit.
- The Company has 60 days to submit to Nasdaq a plan to regain compliance.
- Press Release
For further details see:
Qualigen Therapeutics receives non-compliance notice from Nasdaq for delayed form 10-K filing